ArticleInfluenza and other respiratory viruses2025
Burden of Severe Disease Associated With Influenza, SARS-CoV-2 and RSV in Spain During the 2024-2025 Winter Season.
Article in Influenza and other respiratory viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Correction to "Burden of Severe Disease Associated With Influenza, SARS-CoV-2 and RSV in Spain During the 2024-2025 Winter Season."Influenza and other respiratory viruses · 2026Article
- Underrated, Unvaccinated, Untreated: A Multinational Registry Analysis of Human Metapneumovirus in Hematological Malignancy, Insights From EPICOVIDEHA/EPIRESEHA Registry.Open forum infectious diseases · 2026Article
- Burden of Severe Disease Associated With Influenza, SARS-CoV-2 and RSV in Spain During the 2024-2025 Winter Season.Influenza and other respiratory viruses · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We estimated the burden of influenza, SARS-CoV-2 and RSV from patients hospitalized with acute respiratory infection systematically tested between weeks 40/2024 and 20/2025 in Spain. The hospitalization rate per 100,000 was highest for influenza [67.5 (95% Confidence Interval: 52.5-87.3)] followed by RSV [46.6 (35.4-62.2)] and SARS-CoV-2 [15.8 (10.2-24.6)]. Hospitalization rates peaked in ≥ 60-year-olds and < 5-year-olds, ICU admissions in < 1-year-olds and deaths in ≥ 80-year-olds. Hospitalization for SARS-CoV-2 at 80-85 years was comparable to influenza at 60-65 years, potentially signaling the appropriateness of increasing the COVID-19 vaccination age cut-off. RSV prevention appeared a priority in < 5-year-olds but substantial preventive potential was identified in the elderly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.